Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports
暂无分享,去创建一个
M. Marre | C. Thivolet | A. Scheen | M. Marrè | A.J. Scheen | M. Marre | C. Thivolet
[1] S. Sookoian,et al. Age but not sex may explain the negative effect of arterial hypertension and diabetes on COVID-19 prognosis , 2020, Journal of Infection.
[2] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[3] G. Mancia,et al. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 , 2020, The New England journal of medicine.
[4] F. Strollo,et al. COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used) , 2020, Diabetes Research and Clinical Practice.
[5] M. Zheng,et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease , 2020, Metabolism.
[6] D. Drucker. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications , 2020, Endocrine reviews.
[7] Avik Ray,et al. Metformin in COVID-19: A possible role beyond diabetes , 2020, Diabetes Research and Clinical Practice.
[8] C. Mantzoros,et al. Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next , 2020, Metabolism.
[9] M. Zuin,et al. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome , 2020, Journal of Clinical Virology.
[10] Erkan Cüre,et al. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[11] M. Bajaj,et al. Diabetes and covid-19: a global health challenge , 2020, BMJ Open Diabetes Research & Care.
[12] S. Bhadada,et al. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? , 2020, Diabetes Research and Clinical Practice.
[13] Huihui Ren,et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes , 2020, BMJ Open Diabetes Research & Care.
[14] Hangyuan Guo,et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis , 2020, Journal of Infection.
[15] Fang Lei,et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes , 2020, Cell Metabolism.
[16] Norbert Stefan,et al. Obesity and impaired metabolic health in patients with COVID-19 , 2020, Nature Reviews Endocrinology.
[17] S. Alzghari,et al. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review , 2020, Journal of Clinical Virology.
[18] A J Scheen,et al. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. , 1992, Diabete & metabolisme.
[19] D. Spandidos,et al. Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality , 2020, Molecular medicine reports.
[20] Marc A Pfeffer,et al. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.
[21] K. Khunti,et al. Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2 or COVID‐19) , 2020, Diabetes, obesity & metabolism.
[22] Geltrude Mingrone,et al. Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.
[23] R. José,et al. Does Coronavirus Disease 2019 Disprove the Obesity Paradox in Acute Respiratory Distress Syndrome? , 2020, Obesity.
[24] Ying Yao,et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. , 2020, Journal of the American Society of Nephrology : JASN.
[25] Ritesh Gupta,et al. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[26] R. Ruslami,et al. Type 2 Diabetes and its Impact on the Immune System , 2020, Current diabetes reviews.
[27] P. Ye,et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China , 2020, Hepatology.
[28] H. Jneid,et al. Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the JAHA Editors , 2020, Journal of the American Heart Association.
[29] Wei Wang,et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.
[30] Anna Stachel,et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] Rui Ji,et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.
[32] S. Manfrini,et al. Obesity and SARS‐CoV‐2: A population to safeguard , 2020, Diabetes/metabolism research and reviews.
[33] D. Kass,et al. Obesity could shift severe COVID-19 disease to younger ages , 2020, The Lancet.
[34] D. Cook,et al. Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study , 2015, Intensive Care Medicine.
[35] O. Pfister,et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? , 2020, European heart journal.
[36] A. Malhotra,et al. Potential influences of obstructive sleep apnea and obesity on COVID-19 severity. , 2020, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.
[37] Xuexian Fang,et al. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis , 2020, Research.
[38] S. Legrand-Poels,et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue , 2013, Diabetologia.
[39] G. Iacobellis. COVID-19 and diabetes: Can DPP4 inhibition play a role? , 2020, Diabetes Research and Clinical Practice.
[40] A. Avogaro,et al. Prevalence and impact of diabetes among people infected with SARS-CoV-2 , 2020, Journal of Endocrinological Investigation.
[41] R. Pranata,et al. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[42] Akhtar Hussain,et al. COVID-19 and diabetes: Knowledge in progress , 2020, Diabetes Research and Clinical Practice.
[43] Qingbo Xu,et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 , 2020, Circulation research.
[44] A. Malavazos,et al. Targeting the Adipose Tissue in COVID‐19 , 2020, Obesity.
[45] B. Jiang,et al. Comorbidities and multi-organ injuries in the treatment of COVID-19 , 2020, The Lancet.
[46] G. Umpierrez,et al. Individualizing Inpatient Diabetes Management During the Coronavirus Disease 2019 Pandemic , 2020, Journal of diabetes science and technology.
[47] A. Abdelhafiz,et al. Age, frailty and diabetes – triple jeopardy for vulnerability to COVID-19 infection , 2020, EClinicalMedicine.
[48] Leora I. Horwitz,et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study , 2020, BMJ.
[49] Eun Ji Kim,et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.
[50] B. Kavanagh,et al. Clinical practice. Glycemic control in the ICU. , 2010, The New England journal of medicine.
[51] D. Mathieu,et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation , 2020, Obesity.
[52] David C. Klonoff,et al. Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity , 2020, Metabolism.
[53] N. Caplice,et al. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019? , 2020, Obesity.
[54] G. Paolisso,et al. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients , 2020, Diabetes & Metabolism.
[55] R. Muniyappa,et al. COVID-19 pandemic, coronaviruses, and diabetes mellitus , 2020, American journal of physiology. Endocrinology and metabolism.
[56] R. José,et al. Does Coronavirus Disease 2019 Disprove the Obesity Paradox in Acute Respiratory Distress Syndrome? , 2020, Obesity (Silver Spring, Md.).
[57] Jian Chen,et al. COVID‐19 infection may cause ketosis and ketoacidosis , 2020, Diabetes, obesity & metabolism.
[58] Y. Leo,et al. Association of higher body mass index (BMI) with severe coronavirus disease 2019 (COVID-19) in younger patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] A. Troxel,et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 , 2020, The New England journal of medicine.
[60] J. Saavedra. Angiotensin receptor blockers and COVID-19 , 2020, Pharmacological Research.
[61] Jin-Kui Yang,et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes , 2009, Acta Diabetologica.
[62] M. Rizzo,et al. COVID-19 and diabetes management: What should be considered? , 2020, Diabetes Research and Clinical Practice.
[63] A. Ceriello. Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory , 2020, Diabetes Research and Clinical Practice.
[64] S. Flint,et al. COVID-19 and obesity—lack of clarity, guidance, and implications for care , 2020, The Lancet Diabetes & Endocrinology.
[65] Stephane Heritier,et al. Intensive versus conventional glucose control in critically ill patients. , 2009, The New England journal of medicine.
[66] W. Hong,et al. Hypertransaminasemia in the course of infection with SARS-CoV-2: Incidence and pathogenetic hypothesis , 2020, World journal of clinical cases.
[67] Bo Li,et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China , 2020, Clinical Research in Cardiology.